Clinical trials
Relapsed or Refractory Peripheral T Cell Lymphoma clinical trials
Below are recruiting relapsed or refractory peripheral t cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 1,736 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07776743RecruitingPhase 2
Testing a new oral drug for relapsing-remitting multiple sclerosis (RRMS)
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
Beijing, Beijing MunicipalityAges 18–65 - NCT07778316RecruitingPhase 3
Tarlatamab for small cell lung cancer after first chemotherapy
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
Grand Rapids, MichiganAges 18–99 - NCT04474847RecruitingPhase 3
Abatacept for giant cell arteritis treatment
This Phase 3 trial tests abatacept to treat giant cell arteritis (GCA), a blood vessel inflammation that can cause headaches and vision risk. It’s for people with newly diagnosed or returning (relapsing) GCA with active symptoms in the last 8 weeks.
Rochester, MinnesotaAges 50 years+ - NCT05011422RecruitingPhase 1
Stem cell transplant using half-matched donor for kids with blood cancer
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
St Louis, MissouriAges Up to 30 years - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Birmingham, AlabamaAges 12 years+ - NCT07104032RecruitingPhase 3
Tirabrutinib vs standard therapy for relapsed PCNSL
This study tests a new oral targeted drug called tirabrutinib against a standard treatment combination (rituximab plus temozolomide) for people whose primary central nervous system lymphoma has come back or not responded to prior therapy.
Phoenix, ArizonaAges 18 years+ - NCT06607549RecruitingPhase 1
Targeted drug combo after focused radiation for CNS lymphoma
This trial tests a combination of two targeted drugs (loncastuximab tesirine and rituximab) given after focused radiation (SRS) for people with CNS lymphoma that has come back or not responded to treatment, or who cannot get standard high-dose methotrexate. The goal is to see if this approach is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07751380RecruitingPhase 1
CAR T-cell therapy for children and young adults with certain sarcomas
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
LondonAges 1–24 - NCT06066359RecruitingPhase 1/Phase 2
Cord blood NK cells for NY-ESO-1 positive myeloma
This trial tests a new treatment using cord blood immune cells (NK cells) that are specially designed to target a protein called NY-ESO-1 found on myeloma cells. It is for people with multiple myeloma that has come back or not responded to at least two previous treatments.
Houston, TexasAges 18–80 - NCT07741825Recruiting
Mindfulness training to prevent relapse for peer support workers
This study tests a mindfulness-based program to help people who work as peer support specialists in substance use recovery reduce their risk of relapse. It may help you manage cravings and stay healthy in your role.
Austin, TexasAges 18–100 - NCT04715191RecruitingPhase 1
CAR T therapy for GPC3-positive pediatric solid tumors
This Phase 1 study tests a customized immune-cell treatment (CAR T cells) made to recognize GPC3, a marker found on some tumors. It’s designed for children and young people whose solid tumors have not been cured by standard treatment and who can safely receive this therapy.
Houston, TexasAges 1–21 - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT06021678RecruitingPhase 1/Phase 2
EX103 for relapsed or refractory CD20-positive lymphoma
This trial tests a new drug called EX103 for people whose non-Hodgkin lymphoma (a cancer of the immune system) has come back or not responded to earlier treatments. The goal is to see if EX103 is safe and can shrink tumors.
Zhengzhou, HenanAges 18 years+ - NCT05756322RecruitingPhase 1/Phase 2
Study medicine LBS-007 for relapsed leukemia patients
This trial tests how safe and tolerable LBS-007 is for adults with AML or ALL that has come back or is resistant to treatment. It may help people who can’t use standard therapies or have no proven treatment options.
Tampa, FloridaAges 18–120 - NCT04781634RecruitingPhase 1/Phase 2
CD19 and CD22 targeted CAR-T for hard-to-treat B-ALL
This Phase 1/2 study tests a type of immune therapy (CAR-T cells) made to recognize CD19 and CD22, two markers on B-ALL cells. It is for children and adults with B-ALL that has come back or did not respond to standard treatments, aiming to improve outcomes when other options have failed.
Kunming, YunnanAges 2–75 - NCT05344469Recruiting
Testing new MS medicines in people with active relapsing MS
This study tests different approved “disease-modifying” MS medicines (shots and pills) in adults with relapsing multiple sclerosis that is currently active. It mainly looks at outcomes based on how newly starting—or recently started—treatments are handled for people with recent relapses and mild disability.
Albstadt, Baden-WurttembergAges 18–100 - NCT04237675Recruiting
Study of MS relapses after surgery
This study looks at relapses (new or worsening MS symptoms) after surgery in people with multiple sclerosis (MS). It may help researchers understand what triggers relapse after surgery so better care can be planned.
Athens, AtticaAges 18–70 - NCT03000244Recruiting
Long-term follow-up after stem cell or gene therapy
This study checks how people do long-term after stem cell transplant, cellular therapy, or gene therapy. It may help doctors track longer-term health effects and recovery and improve future care.
Bethesda, MarylandAges 4–120 - NCT02312830Enrolling by invitation
Study of long-term transplant survivors at one Belgian hospital
This study invites adults who had a donor (allogeneic) transplant at KU Leuven long ago to share health information during a scheduled checkup. It may help researchers better understand long-term outcomes and support needs after transplant.
Ages 18–100 - NCT05416775RecruitingPhase 1/Phase 2
Test drug SHR-8068 for advanced lung cancer
This trial tests SHR-8068 in people with advanced non-small cell lung cancer (NSCLC). It may help by controlling cancer after standard treatments have not worked, and it’s designed to find the right way to give the drug.
Hefei, AnhuiAges 18–75 - NCT06430814Recruiting
Blood test to predict nerve damage from paclitaxel
This study looks at whether certain markers in your blood can predict nerve damage from paclitaxel chemotherapy. If you join, researchers will monitor your nerve health during treatment to better understand and possibly prevent side effects.
OdenseAges 18 years+ - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+ - NCT06773091RecruitingPhase 1
NK cell therapy for advanced solid tumors
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
BeijingAges 18–70 - NCT07191431Recruiting
Study of drug combo for returning brain lymphoma
This trial tests a combination of drugs (Orelabrutinib and Selinexor) with either Methotrexate, Thiotepa, or Temozolomide for people whose brain lymphoma has come back or not responded to prior treatment. The goal is to see if this combination is safe and effective.
Shanghai, Shanghai MunicipalityAges 14–80
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory peripheral t cell lymphoma?
- Yes. Clin2 currently lists 1,736 recruiting relapsed or refractory peripheral t cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory peripheral t cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory peripheral t cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Relapsed/Refractory Peripheral T Cell Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Relapsed or Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Relapsed/Refractory Large B-Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.